Clinical trials: Liver Tumour
Liver Cancer, Lung Cancer
Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors
The goal of this clinical research study is to find the highest tolerable dose of ipilimumab and stereotactic body radiation therapy (SBRT).
- Trial name
- NCT02239900
- Testing
- Ipilimumab, Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 143 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Alcoholic Fatty Liver Disease
The Effect of an RBAC Supplement (BRM4) on NAFLD
The purpose of this study is to investigate the effects of Rice Bran Arabinoxylan Compound (RBAC) on outcome variables in persons with non-alcoholic fatty liver disease (NAFLD).
- Trial name
- NCT02568787
- Testing
- rice bran arabinoxylan compound (RBAC)
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- University of Miami
Hepatitis B, Cirrhosis
Prevention of Recurrent Hepatitis B After Liver Transplantation
Hepatitis B accounts for approximately 5000 deaths per year in the United States. Liver transplantation offers the only hope for patients who develop end-stage liver disease.
- Conditions
- Hepatitis B, Cirrhosis, Acute Liver Failure, Hepatocellular Carcinoma
- Trial name
- NCT00059267
- Testing
- HBIG, Epivir, Hepsera
- Where
- United States
- Volunteers
- 317 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Ocular Melanoma, Uveal Melanoma
Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma
This study will evaluate patients who have ocular melanoma that has spread from the eye to the liver: Patients in the study will be treated with Melphalan/HDS up to 6 total treatments and will be followed until death.
- Trial name
- FOCUS (NCT02678572)
- Testing
- Melphalan/HDS
- Where
- 22 sites in United States, Austria and 7 more
- Volunteers
- 102 people
- Sponsor
- Delcath Systems Inc.
Carcinoma, Hepatocellular
Study on the Efficacy and Safety of Conversion Therapy in Patients With Initially Unresectable Hepatocellular Carcinoma
To evaluate the efficacy and safety of conversion therapy in patients with initially unresectable hepatocellular carcinoma (uHCC).
- Trial name
- NCT06365034
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Qianfoshan Hospital
Liver Diseases, Fibrosis, Liver
Liver Cancer Prevention Randomized Control Trial
To determine the effectiveness of a behaviorally-based tailored disease management intervention in patients with fibrosis or steatosis and risk factors for cirrhosis.
- Conditions
- Liver Diseases, Fibrosis, Liver, Cirrhosis, Liver
- Trial name
- NCT05196867
- Testing
- Intervention Group, Control Group
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatocellular Carcinoma
The Surveillance of Hepatocellular Carcinoma
Early detection of hepatocellular carcinoma is vita to the prognosis of patient. In this study, the occurrence and development of liver cancer were supervised by imaging examination, and the dysplastic nodules will be…
- Trial name
- NCT05286099
- Testing
- Imaging examination and/or blood test
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Chinese PLA General Hospital
Liver Tumor, Hepatocellular Carcinoma
NeuWave Microwave Ablation HCC China Study
This is a single-arm, prospective, multicenter, study. Individuals who are assessed for microwave (MW) ablation of HCC in accordance with their institution's standard of care (SOC), who meet study entry criteria and sign the…
- Trial name
- NW (NCT03783871)
- Testing
- Microwave ablation
- Where
- 4 sites in China
- Volunteers
- 135 people
- Sponsor
- Ethicon, Inc.
Hepatocellular Carcinoma Non-resectable, Cholangiocarcinoma Non-resectable
TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors
This study will evaluate the efficacy and safety of TACE combined with immune checkpoint inhibitors to treat unresectable hepatocellular carcinoma.
- Conditions
- Hepatocellular Carcinoma Non-resectable, Cholangiocarcinoma Non-resectable, Liver Metastases, Liver Malignant Tumors
- Trial name
- TIKET (NCT06487663)
- Testing
- TACE with ICI
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
NSCLC, Prostate Cancer
Clinical Trial of TB511 in Advanced Solid Tumors
1. Study population [TB511 Monotherapy Cohort for Phase 1 and Phase 2a Clinical Trial] Patients with advanced solid tumors who are either refractory or intolerant to standard of care (SoC).
- Conditions
- NSCLC, Prostate Cancer, Colorectal Cancer, Hepatocellular Carcinoma
- Trial name
- NCT06400160
- Testing
- TB511, Keytruda
- Volunteers
- 12 people
- Sponsor
- Twinpig Biolab, Inc.
Hepatocellular Carcinoma
Construction of a Recurrence Risk Prediction Model for Liver Resection Based on Drug Sensitivity of Patient-derived Hepatocellular Carcinoma Organoid
Liver cancer is the sixth most common malignant tumor worldwide and the third leading cause of cancer-related deaths. China is a high-risk area for liver cancer, accounting for approximately 55% of primary liver cancer worldwide.
- Trial name
- NCT06699524
- Testing
- in vitro （chemotherapy）, Adjuvant TACE（Adjuvant Transarterial Chemoembolization）
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Shen Feng
Liver Cancer, Metastatic Cancer
Hepatic Arterial Infusion With Melphalan in Treating Patients With Unresectable Liver Cancer
RATIONALE: Heating melphalan to several degrees above body temperature and infusing it to the affected area directly around the tumor may kill more tumor cells.
- Trial name
- NCT00030082
- Testing
- isolated perfusion, melphalan
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC
Compare the effect of liver transplantation (LT) plus ADV-TK gene therapy versus LT only in advanced primary hepatocellular carcinoma.
- Trial name
- NCT03313596
- Testing
- ADV-Tk, LT
- Where
- 11 sites in China
- Volunteers
- 180 people
- Sponsor
- Huazhong University of Science and Technology
Hepatocellular Carcinoma (HCC), DGF
A Retrospective Cohort Study on Predicting Delayed Graft Function in Liver Transplant Patients with Hepatocellular Carcinoma: a Nomogram and Machine Learning Approaches.
Background: This study aimed to develop a predictive model for delayed graft function (DGF) in liver transplant patients with hepatocellular carcinoma (HCC) based on preoperative biochemical indicators, using both logistic…
- Trial name
- NCT06626724
- Testing
- Liver transplantation
- Where
- China
- Volunteers
- 131 people
- Sponsor
- Jian You
HCC - Hepatocellular Carcinoma
A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors
This study aims to explore the value of the 'HAIC Apatinib Camrelizumab' triple regimen for perioperative treatment of resectable hepatocellular carcinoma.
- Trial name
- NCT07618546
- Testing
- Camrelizumab (anti-PD-1 inhibitor), Apatinib Mesylate Tablets, FOLFOX-HAIC
- Volunteers
- 208 people
- Sponsor
- Henan Cancer Hospital
Liver Cancer
To Explore the Safety and Efficacy of Intravenous Infusion of Different Doses of Lidocaine in Patients
All patients who met the inclusion criteria were randomly divided into four groups, 30 cases in each group, which were lidocaine group 1, lidocaine group 1.5, lidocaine group 2, and the placebo group In lidocaine group 1…
- Trial name
- NCT05369650
- Testing
- Lidocaine Hydrochloride, Injectable
- Where
- China
- Volunteers
- 120 people
- Sponsor
- West China Hospital
Hepatocellular Carcinoma
Sorafenib VS TACE in HCC Patients With Portal Vein Invasion
The investigators are going to compare the therapeutic effect of sorafenib and transarterial chemoembolization in advanced hepatocellular carcinoma with major branch of portal vein invasion.
- Trial name
- NCT01480817
- Testing
- Sorafenib, TACE for HCC with portal vein invasion
- Where
- South Korea
- Volunteers
- 2 people
- Sponsor
- Seoul National University Hospital
Cirrhosis, Neoplasms
Chemotherapy and Liver Cirrhosis in Frequently-associated Cancers
Cirrhosis and cancers of the upper digestive tract, colorectal and ENT share common risk factors. Liver cirrhosis can change the elimination of cancer drugs.
- Trial name
- CHIMIOSE (NCT04179773)
- Testing
- Current care study
- Where
- 2 sites in France
- Volunteers
- 7 people
- Sponsor
- University Hospital, Lille
Hepatocellular Carcinoma, Portal Hypertension
Impact of Clinical Evident Portal Hypertension on HCC With TACE (CHANCE-CHESS 2301)
The purpose of this study is to discuss the prognostic value of CEPH among HCC patients underwent TACE treatment, its impact on overall survival, and try to stratify patient cohorts for a better treatment strategy.
- Trial name
- NCT05703750
- Testing
- TACE ± Systemic therapy
- Where
- 2 sites in China
- Volunteers
- 228 people
- Sponsor
- Zhongda Hospital
HCC - Hepatocellular Carcinoma, TP53 Gene Mutation
A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma
This study aims to evaluate the effectiveness and safety of a combination therapy with Fuxinqibai monoclonal antibody, Tislelizumab, and Lenvatinib in patients with advanced, unresectable TP53-mutated hepatocellular carcinoma…
- Conditions
- HCC - Hepatocellular Carcinoma, TP53 Gene Mutation, Unresectable, Resistant Cancer
- Trial name
- NCT07535840
- Testing
- Firsekibart + Tislelizumab + Lenvatinib
- Volunteers
- 25 people
- Sponsor
- Tongji Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.